Faruqi & Faruqi, LLP is investigating the claims on behalf of Regeneron Pharmaceuticals investor Investing.com

admin12 hours ago

0 0 3 minutes read

Faruqi & Faruqi, LLP securities litigation partner James (Josh) Wilson encourages investors who have suffered losses greater than $100,000 in Regeneron (NASDAQ: ) to contact him directly to discuss their options

If you have suffered losses greater than $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and want to discuss your legal rights, call a Faruqi & Faruqi partner Josh Wilson direct on 877-247-4292 or 212-983-9330 (ext. 1310).

[You may also click here for additional information]

New York, New York–(Newsfile Corp. – January 9, 2025) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc . (“Regeneron” or the “Company” ) (NASDAQ: REGN ) and reminds investors of The deadline is March 10, 2025 to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The company has recovered hundreds of millions of dollars for investors since its inception in 1995. See www.faruqilaw.com.

As set forth below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the following: (1) that Regeneron paid credit card fees to distributors subject to that distributors did not charge Eyle users more for credit card use; (2) that these payments subsidized the prices customers paid when using credit cards to purchase Eyle; (3) that, as a result, Regeneron offered a price concession that lowered the selling price of Eylee; (4) that Regeneron’s price discounts provided a competitive advantage, as retinal practices were sensitive to higher prices when using credit cards to purchase anti-VEGF drugs; (5) that, as a result of the foregoing, Regeneron erroneously inflated reported sales of Eylea; (6) that Regeneron, by failing to report its payment of credit card fees as price concessions, overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) that, as a result of the above, the defendant’s positive statements about the Company’s business, operations and prospects were materially misleading and/or lacked a reasonable basis.

On April 10, 2024, the US Department of Justice (“DOJ”) announced that it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the company failed to report millions of dollars in rebates given to drug distributors in the form of reimbursed credit card fees. As a result, the DOJ claims that the ASP for Regeneron’s Eylea drug was inflated, which inappropriately increased Medicare reimbursements. By reimbursing credit card fees, Regeneron subsidized treatment costs, thereby gaining a competitive advantage over other anti-VEGF treatments.

Following this news, Regeneron’s stock price fell $31.50, or 3.36%, over two consecutive trading days to close at $904.70 on April 12, 2024, on unusually heavy trading volume.

Then, on October 31, 2024, before the market opened, Regeneron released its third quarter 2024 financial results, revealing a lag in US net sales for Eyle HD and Eyle. The company reported that sales rose just 3% from the third quarter of 2023, with quarterly Eyle HD sales of just $392 million, missing consensus estimates of $415 million to $425 million. The company also revealed that “[n]sales of EYLEA products in the third quarter of 2024 were adversely affected by a lower net selling price compared to the third quarter of 2023.” Following this news, Reuters reported that the company “reported weaker-than-expected quarterly sales of a higher-dose version of its hit drug for eye diseases of Eyle.”

Following the news, Regeneron’s stock price fell $84.59, or 9.2%, to close at $838.20 per share on October 31, 2024, on unusually high trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of the class members who directs and oversees the litigation on behalf of the putative class. Any putative class member may propose to the Court to serve as lead plaintiff through counsel of his or her choosing, or may choose to do nothing and remain an absent class member. Your ability to participate in any recovery is not affected by the decision whether or not you will be the lead plaintiff.

Faruqi & Faruqi, LLP also encourages anyone with information about Regeneron’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.

Advertising of lawyers. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your specific case. All communications will be treated confidentially.

To view the original version of this press release, visit https://www.newsfilecorp.com/release/236509

Source link